Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CASI Signs $10 Million Out-licensing of CD38 for Autoimmune Indications to Tianshi

publication date: May 24, 2022

CASI Pharma, a Maryland-Beijing biopharma, will sublicense global rights to develop its anti-CD38 candidate for autoimmune conditions to Beijing Tianshi Tongda Pharmaceuticals. Tianshi will make a $10 million upfront payment to CASI, while CASI will contribute $3 million to Tianshi’s $21 million venture funding in exchange for a 15% Tianshi stake. Although the agreement is supposed to be global, CASI will book all US revenues from the CD38 for autoimmune indications and (possibly) for hematology-autoimmune indications in China. CASI originally acquired CID-103 as a therapy for multiple myeloma. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital